Abstract：
UNASSIGNED: Biologic therapies play a crucial role in the treatment of severe asthma. Tezepelumab, a human monoclonal antibody (mAb), inhibits thymic stromal lymphopoietin, a pivotal factor in the pathophysiology of asthma. Although randomized clinical trials have demonstrated the efficacy of Tezepelumab, evidence gaps remain in real-world scenarios.
UNASSIGNED: We sought investigate Tezepelumab\'s response in a clinical setting, focusing on patients who previously failed to other asthma mAbs.
UNASSIGNED: Real-life study with severe uncontrolled asthma patients despite mAb treatment, requiring a switch to Tezepelumab. Follow-up was done four to six months after initiation of Tezepelumab. The primary endpoint was to evaluate the response in patients with poor response or intolerance to other mAbs.
UNASSIGNED: Nine patients were followed up during 7 months. Patients were predominantly middle-aged females with eosinophilic or eosinophilic-allergic phenotypes. Patients had a median failure rate of 2 mAbs (IQR 2-3), with an uncontrolled asthma (median of 2 severe exacerbations the previous year, airflow obstruction and 78% corticosteroid dependence). Tezepelumab demonstrated after 4 to 6 months of treatment reduce corticosteroid dependence (complete withdrawal in 2/7 patients), no exacerbations in 6/9, symptoms control improvement (Asthma Control Test score improved in 5/9) and modulate lung function (improving in 3/9 patients). These findings align with clinical trial results, suggesting Tezepelumab\'s potential in real-world settings.
UNASSIGNED: In real-world scenarios, despite the study\'s limitations, our results underscore Tezepelumab\'s promise as a therapeutic option for uncontrolled severe asthma, and may be useful for non-responders to other mAbs. Further studies are needed to corroborate these findings.
UNASSIGNED: We sought investigate Tezepelumab\'s response in a clinical setting, focusing on patients who previously failed to other asthma mAbs.
UNASSIGNED: Real-life study with severe uncontrolled asthma patients despite mAb treatment, requiring a switch to Tezepelumab. Follow-up was done four to six months after initiation of Tezepelumab. The primary endpoint was to evaluate the response in patients with poor response or intolerance to other mAbs.
UNASSIGNED: Nine patients were followed up during 7 months. Patients were predominantly middle-aged females with eosinophilic or eosinophilic-allergic phenotypes. Patients had a median failure rate of 2 mAbs (IQR 2-3), with an uncontrolled asthma (median of 2 severe exacerbations the previous year, airflow obstruction and 78% corticosteroid dependence). Tezepelumab demonstrated after 4 to 6 months of treatment reduce corticosteroid dependence (complete withdrawal in 2/7 patients), no exacerbations in 6/9, symptoms control improvement (Asthma Control Test score improved in 5/9) and modulate lung function (improving in 3/9 patients). These findings align with clinical trial results, suggesting Tezepelumab\'s potential in real-world settings.
UNASSIGNED: In real-world scenarios, despite the study\'s limitations, our results underscore Tezepelumab\'s promise as a therapeutic option for uncontrolled severe asthma, and may be useful for non-responders to other mAbs. Further studies are needed to corroborate these findings.
摘要：
背景。生物疗法在严重哮喘的治疗中起着至关重要的作用。Tezepelumab,人单克隆抗体（mAb），抑制胸腺基质淋巴细胞生成素，哮喘病理生理学的一个关键因素。尽管随机临床试验已经证明了Tezepelumab的疗效，在现实世界的场景中仍然存在证据差距。目标。我们试图调查Tezepelumab在临床环境中的反应，专注于以前其他哮喘mAbs失败的患者。方法。尽管有mAb治疗，但对严重未控制的哮喘患者的现实生活研究，需要改用Tezepelumab.在Tezepelumab开始后4至6个月进行随访。主要终点是评估对其他mAb反应不良或不耐受的患者的反应。结果。9例患者随访7个月。患者主要是嗜酸性粒细胞或嗜酸性粒细胞过敏表型的中年女性。患者的中位失败率为2mAb（IQR2-3），患有不受控制的哮喘（前一年的中位数为2次严重加重，气流阻塞和78%皮质类固醇依赖性)。Tezepelumab在治疗4至6个月后证明可减少皮质类固醇依赖（2/7患者完全戒断），6/9无恶化，症状控制改善（哮喘控制测试评分5/9改善）和调节肺功能（3/9患者改善）。这些发现与临床试验结果一致，表明Tezepelumab在现实世界中的潜力。结论。在现实世界的场景中,尽管这项研究的局限性，我们的结果强调了Tezepelumab作为不受控制的严重哮喘的治疗选择的承诺，并且可能对其他单克隆抗体的无应答者有用。需要进一步的研究来证实这些发现。
